阿司匹林与慢性肾脏病患者初始心血管及出血风险
本研究基于韩国全国队列数据,纳入eGFR 15–59 ml/min/1.73 m²且无既往心血管病的40–79岁人群,倾向评分匹配15,861例新处方阿司匹林100 mg/d者与79,305例非使用者。中位随访6.9±2.9年,阿司匹林与主要心血管复合终点无显著关联(HR 0.93,95%CI 0.86–1.04),但大出血住院风险升高(HR 1.45,95%CI 1.32–1.59)。
要点
- CKD G3–G4且无既往心血管病患者,阿司匹林未显著降低心血管事件风险。
- 阿司匹林使用与大出血住院风险增加相关(HR 1.45)。
- CKD患者一级预防处方阿司匹林需谨慎权衡获益与出血风险。
核心结论
- 在CKD G3–G4且无既往心血管病的患者中,阿司匹林使用与非致命性动脉粥样硬化性心血管病或心血管死亡风险无显著关联。
- 阿司匹林使用与主要出血住院风险升高相关。
研究设计与样本
- 基于韩国全国队列数据的倾向评分匹配研究。
- 纳入40–79岁、eGFR 15–59 ml/min/1.73 m²且2011–2016年接受常规健康检查的个体。
- 15,861例新处方阿司匹林100 mg/d者与79,305例非使用者进行倾向评分匹配。
主要发现
- 平均随访6.9±2.9年,阿司匹林使用者与非使用者主要疗效终点发生率分别为8.0与9.0/1000人年。
- 阿司匹林起始治疗与主要疗效终点无显著关联(HR 0.93,95%CI 0.86–1.04)。
- 主要安全终点大出血在阿司匹林使用者中更常见(6.7 vs 4.7/1000人年)。
- 阿司匹林使用者 vs 非使用者大出血风险HR 1.45(95%CI 1.32–1.59)。
关键数值与推荐
- 阿司匹林剂量为100 mg/d。
- 主要疗效终点为非致命性动脉粥样硬化性心血管病或心血管死亡的复合终点。
- 主要安全终点为颅内或胃肠道出血导致的住院。
临床怎么用
- 对CKD G3–G4且无既往心血管病患者,启动阿司匹林一级预防前应仔细评估出血风险。
- 不应仅因CKD存在而常规处方阿司匹林进行心血管一级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The association between aspirin use and risk of the first cardiovascular event was NS in patients with CKD. Compared with nonusers, aspirin users had an increased risk of significant bleeding events. Aspirin prescription for the primary prevention of cardiovascular disease in patients with CKD needs careful consideration. BACKGROUND: Despite the high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear. This study aimed to investigate the association between aspirin initiation in adults with CKD without prior cardiovascular disease (CVD) and the first cardiovascular and bleeding events using Korean nationwide cohort data. METHODS: Among individuals aged 40–79 years with an eGFR between 15 and 59 ml/min per 1.73 m2 who underwent routine health examinations between 2011 and 2016, 15,861 individuals who were newly prescribed aspirin at a dose of 100 mg/d were matched with 79,305 aspirin non-users by propensity score matching. The primary efficacy outcome was a composite of nonfatal atherosclerotic CVD or cardiovascular death. The primary safety outcome was hospitalization due to intracranial or gastrointestinal bleeding. RESULTS: During a mean follow-up of 6.9±2.9 years, the incidence rates for the primary efficacy outcome in aspirin users and nonusers were 8.0 and 9.0 per 1000 person-years, respectively. Aspirin therapy initiation was not associated with the primary efficacy outcome (hazard ratio, 0.93; 95% confidence intervals, 0.86 to 1.04). However, the primary safety outcome of major bleeding was more frequent in aspirin users than in nonusers (6.7 versus 4.7 per 1000 person-years). The hazard ratio for this outcome in aspirin users versus nonusers was 1.45 (95% confidence intervals, 1.32 to 1.59). CONCLUSIONS: No association was observed between aspirin use and the risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.
引用
- Kim JY, Lim H, Park CH, et al. Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease. Clin J Am Soc Nephrol. 2024. PMID: 39774415. doi:10.2215/CJN.0000000619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。